welgenaleucel
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03811457)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04296461 | Phase 1 | Jul 1, 2020 | Government of Taiwan, UWELL Biopharma |
| NCT03811457 | N/A | Jun 1, 2017 | Liaocheng People's Hospital, UWELL Biopharma |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UWELL Biopharma | For profit | 2 | 2 | 2 | 2017 |
| Government of Taiwan | Government | 1 | 0 | 1 | 2020 |
| Liaocheng People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2017 |
3 organizations
Page 1 / 1